Twist Bioscience Corporation (TWST) Stock
TWST Key Statistics
About Twist Bioscience Corporation
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
CEO: Emily Marine Leproust. Company website
TWST — Frequently Asked Questions
What is the TWST stock price today?
Twist Bioscience Corporation (TWST) trades at $122.59, down 7.22% on the day, as of Nov 12, 2026 09:30 UTC.
What is Twist Bioscience Corporation's market cap?
Twist Bioscience Corporation has a market capitalisation of $8.07B, calculated from the live TWST share price and shares outstanding.
What is the P/E ratio of TWST?
TWST has no meaningful price-to-earnings ratio: Twist Bioscience Corporation lost $2.23 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Twist Bioscience Corporation make?
Twist Bioscience Corporation generated revenue of $431.80M over the trailing twelve months, which puts the stock at 18.69 times sales.
What is the 52-week range for TWST?
TWST has traded between $23.30 and $219.71 over the past 52 weeks, and the last price is 44.2% below that high.
Is Twist Bioscience Corporation profitable?
No. Twist Bioscience Corporation is loss-making, with a net margin of -31.66% over the trailing twelve months.
What is the analyst price target for TWST?
Wall Street analysts rate TWST Buy, with an average price target of $153.70, 25.4% above the current price.
What sector is Twist Bioscience Corporation in?
Twist Bioscience Corporation is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Twist Bioscience Corporation?
Emily Marine Leproust is the chief executive of Twist Bioscience Corporation, which employs 979 people.
Where can I track TWST in real time?
QFI Terminal shows TWST with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TWST live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TWST in Terminal See plans